MONTREAL – April 24, 2026 – The Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) will simultaneously publish seven original research studies at the SCAI 2026 Scientific Sessions & CAIC-ACCI Summit , held April 23–25, 2026, in Montréal, Canada, reflecting the journal’s continued growth as a premier platform for timely, clinically relevant science.
“This original research reflects both the breadth of interventional cardiology and the pace at which new evidence is shaping clinical practice,” said Alexandra J. Lansky, MD, MSCAI , Editor-in-Chief of JSCAI. “Simultaneous publication ensures that new findings are immediately accessible to clinicians and researchers worldwide, allowing the field to engage with the data in real time. From cardiometabolic therapies and structural heart disease to peripheral intervention and shock care, this body of work highlights where the field is moving and how we continue to refine care for increasingly complex patient populations.”
All JSCAI original research simultaneously published at SCAI 2026 Scientific Sessions is embargoed until its publication time. These articles include:
Diurnal Variation in Mechanical Circulatory Support Initiation and Associated Outcomes
Publishing April 23 at 8:00 a.m. ET
https://www.jscai.org/article/S2772-9303(26)01129-4/fulltext
In patients with cardiogenic shock requiring mechanical circulatory support (MCS), timing of device initiation did not affect outcomes. Across more than 1,100 ICU patients, mortality, bleeding, kidney injury, and time to support were similar whether MCS was initiated during the day or overnight. The findings suggest consistent, around-the-clock readiness for advanced shock care, minimizing the traditional “off-hours effect,” and supporting reliable delivery of high-acuity care regardless of the time of day. Presentation details.
Cardiovascular Impact of Endovascular Revascularization in Chronic Limb-Threatening Ischemia Versus Claudication: A Contemporary Real-World Analysis
Publishing April 23 at 9:00 a.m. ET
https://www.jscai.org/article/S2772-9303(26)01119-1/fulltext
Patients undergoing endovascular revascularization for chronic limb-threatening ischemia (CLTI) faced a persistently higher risk of short- and long-term cardiovascular outcomes compared with those treated for claudication, despite similar procedures. The analysis highlights the profound systemic risk associated with CLTI and reinforces the need for intensified secondary prevention and longitudinal care beyond the procedure itself. Presentation details .
Association of Tirzepatide Use with Clinical Outcomes After TAVR in Obese Patients: A Propensity-Matched Real-World Study
Publishing April 23 at 10:50 a.m. ET
https://www.jscai.org/article/S2772-9303(26)01131-2/fulltext
For patients with obesity undergoing transcatheter aortic valve replacement (TAVR), use of tirzepatide was associated with lower rates of heart failure and acute kidney injury at one year. The findings suggest that metabolic optimization may be a valuable adjunctive strategy for patients undergoing TAVR, signaling a growing intersection between cardiometabolic management and structural heart care. Presentation details .
Association of Peri-Procedural GLP-1 Receptor Agonist Therapy With 1-Year Major Adverse Cardiovascular Events After Carotid Artery Stenting: A Propensity-Matched Analysis
Publishing April 24 at 9:00 a.m. ET
https://www.jscai.org/article/S2772-9303(26)01134-8/fulltext
Among patients undergoing carotid artery stenting, those receiving GLP‑1 receptor agonists during the peri‑procedural period experienced lower rates of major adverse cardiovascular events at one year, driven primarily by reduced mortality. While hypothesis‑generating, these findings raise the possibility that GLP-1 RA may have a role in secondary prevention following carotid revascularization, particularly in patients with concomitant type 2 diabetes or obesity. Presentation details .
Angiographic and electrocardiographic characteristics of patients with NSTEMI and COVID-19
Publishing April 24 at 12:00 p.m. ET
https://www.jscai.org/article/S2772-9303(26)01072-0/fulltext
Core laboratory–adjudicated data show that NSTEMI patients with COVID-19 present with diffuse ECG changes, high thrombotic burden, fewer identifiable culprit lesions, lower rates of procedural revascularization success, and higher mortality compared with pre-pandemic cohorts. The findings provide new insight into how COVID-19 alters coronary pathology and complicates management in acute coronary syndromes. Presentation details .
Persistent One-Year Mortality Gradient After STEMI and COVID-19: Long-Term Outcomes from the NACMI Registry (Featured Clinical Science)
Publishing April 24 at 11:00 a.m. ET
https://www.jscai.org/article/S2772-9303(26)01142-7/fulltext
New data from the NACMI registry show that excess mortality in COVID-19-era STEMI extends far beyond hospitalization. One-year mortality reached 45% in COVID-positive patients compared with 11% in historical controls, revealing a persistent and substantial risk gap. The findings underscore both the long-term impact of COVID-19 on cardiovascular patients and the broader effects of disrupted care during the pandemic. Presentation details .
Sex-Stratified Outcomes of Drug-Eluting Resorbable Scaffolds versus Balloon Angioplasty for Below-the-Knee Revascularization: Insights From the LIFE-BTK Trial
Publishing April 24 at 4:00 p.m. ET
https://www.jscai.org/article/S2772-9303(26)01135-X/fulltext
In the LIFE-BTK trial, drug-eluting resorbable scaffolds outperformed balloon angioplasty for below-the-knee revascularization, with consistent benefit across both men and women. The findings support the durability of scaffold-based therapy in chronic limb-threatening ischemia and highlight the importance of evaluating outcomes across patient subgroups. Presentation details .
About SCAI Scientific Sessions 2026
The SCAI Scientific Sessions annual meeting convenes nearly 2,000 of the world’s premier clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine. With 500+ faculty and hundreds of abstracts, experts in the field work together to share the latest clinical data, procedural guidance, and advanced expertise. Highlights include live cases, featured clinical research, new SCAI clinical documents, case-based learning, and keynote speakers. For more information, visit https://scai.org .
About the Society for Cardiovascular Angiography & Interventions (SCAI)
The Society for Cardiovascular Angiography & Interventions, established in 1978, stands as the primary nonprofit medical society dedicated to representing invasive and interventional cardiology. SCAI's mission is to guide the global interventional cardiovascular community by fostering education, advocacy, research, and upholding standards for quality patient care. For more than 40 years, SCAI has exemplified professional excellence and innovation worldwide, cultivating a reputable community of over 5,000 members committed to advancing medical science and providing life-saving care for individuals, both adults and children, affected by cardiovascular disease.
For more information about the SCAI 2026 Scientific Sessions, visit https://www.scai.org/education-and-events/events-schedule/scai-2026-scientific-sessions-caic-acci-summit . Follow @SCAI on X for the latest heart health news and use #SCAI2026 to follow the latest discussions.